Wlazlo Nick, van Greevenbroek Marleen M J, Ferreira Isabel, Jansen Eugene H J M, Feskens Edith J M, van der Kallen Carla J H, Schalkwijk Casper G, Bravenboer Bert, Stehouwer Coen D A
Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands,
Acta Diabetol. 2015 Apr;52(2):337-48. doi: 10.1007/s00592-014-0646-3. Epub 2014 Oct 1.
Several markers of iron metabolism have been associated with insulin resistance (IR) and type 2 diabetes mellitus in cross-sectional studies. However, prospective data on these associations are scarce, and it is currently unclear in which tissues iron metabolism may contribute to IR. Therefore, we investigated whether markers of iron metabolism were associated with IR in muscle, liver, and adipocytes, and with glucose intolerance over a 7-year follow-up period.
Serum ferritin, transferrin, total iron, non-transferrin-bound iron, and transferrin saturation were determined at baseline of a prospective cohort study in 509 individuals (60 % men, age 59 ± 6.9 years, body mass index 28.5 ± 4.3). Both at baseline and after a 7-year follow-up (n = 386), measures of glucose, insulin (during glucose tolerance tests), and non-esterified fatty acids were obtained. Using generalized estimating equations, we investigated associations between baseline iron markers and indices of muscle, liver, and adipocyte insulin resistance (adipocyte IR), as well as glucose intolerance, over the 7-year period.
Over a 7-year period, baseline serum ferritin (per 10 μg/L increase) was positively associated with homeostasis model assessment insulin resistance (HOMA2-IR) [β = 0.77 % (95 % CI 0.50-1.03)], hepatic insulin resistance (hepatic IR) [β = 0.39 % (0.23-0.55)], adipocyte IR [β = 1.00 % (0.65-1.35)], and AUCglucose [β = 0.32 % (0.18-0.46)] after adjustment for several covariates, including inflammatory markers (all p < 0.001). Similarly, serum transferrin (per 0.1 g/L) was associated with HOMA2-IR [β = 2.66 % (1.55-3.78)], hepatic IR [β = 1.16 % (0.47-1.85)], adipocyte IR [β = 3.75 % (2.27-5.25)], and AUCglucose [β = 1.35 % (0.74-1.96)] over 7 years.
Iron metabolism and related factors may contribute to IR in muscle, liver, and adipocytes, eventually leading to impaired glucose metabolism and hyperglycaemia.
在横断面研究中,铁代谢的几种标志物已与胰岛素抵抗(IR)和2型糖尿病相关联。然而,关于这些关联的前瞻性数据很少,目前尚不清楚铁代谢可能在哪些组织中导致IR。因此,我们调查了铁代谢标志物是否与肌肉、肝脏和脂肪细胞中的IR以及7年随访期内的葡萄糖耐量异常相关。
在一项前瞻性队列研究的基线时,对509名个体(60%为男性,年龄59±6.9岁,体重指数28.5±4.3)测定血清铁蛋白、转铁蛋白、总铁、非转铁蛋白结合铁和转铁蛋白饱和度。在基线和7年随访后(n = 386),获取葡萄糖、胰岛素(在葡萄糖耐量试验期间)和非酯化脂肪酸的测量值。使用广义估计方程,我们研究了基线铁标志物与肌肉、肝脏和脂肪细胞胰岛素抵抗(脂肪细胞IR)指数以及7年内葡萄糖耐量异常之间的关联。
在7年期间,调整包括炎症标志物在内的几个协变量后,基线血清铁蛋白(每增加10μg/L)与稳态模型评估胰岛素抵抗(HOMA2-IR)[β = 0.77%(95%CI 0.50 - 1.03)]、肝脏胰岛素抵抗(肝脏IR)[β = 0.39%(0.23 - 0.55)]、脂肪细胞IR [β = 1.00%(0.65 - 1.35)]和葡萄糖曲线下面积(AUCglucose)[β = 0.32%(0.18 - 0.46)]呈正相关(所有p < 0.001)。同样,血清转铁蛋白(每0.1g/L)与7年内的HOMA2-IR [β = 2.66%(1.55 - 3.78)]、肝脏IR [β = 1.16%(0.47 - 1.85)]、脂肪细胞IR [β = 3.75%(2.27 - 5.25)]和AUCglucose [β = 1.35%(0.74 - 1.96)]相关。
铁代谢及相关因素可能导致肌肉、肝脏和脂肪细胞中的IR,最终导致葡萄糖代谢受损和高血糖症。